Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?



Idera Pharmaceuticals (IDRA) Climbs on Positive Top-line Data from IMO-8400 Phase 2 Trial

By  +Follow March 27, 2014 11:11AM
Tickers Mentioned:

It’s been a wild week for Idera Pharmaceuticals (IDRA). What started as a modest decline on March 19 after the stock bumped against its rising resistance level at about $6.85 a share turned into a blood bath on Monday when Summer Street Research Partners analysts expressed skepticism about the effectiveness of IMO-8400, the company’s lead therapy. Shares plummeted, and kept falling throughout the week. However, while Thursday brought more losses, it also brought an opinion from Piper Jaffray analysts that ran counter to Summer Street, calling the sell-off premature and overblown.

Now, for the time being at least, it appears as though Piper Jaffray had the right idea. The stock is up over 10 percent in early trading after the release of top-line data from its Phase 2 trial for IMO-8400 that appears to be broadly positive.

Shares gapped up 16.2 percent to $4.51 a share at the opening bell, fell sharply to just under $4.30 immediately afterwards, then quickly began a buying run that pushed the stock as high as $4.75 a share just before 10am ET, a 22.4 percent gain. The stock retreated again, though, falling back below its opening price as the morning wore on.

The phase 2 trial was a double-blind placebo controlled clinical trial involving 32 patients with moderate-to-severe plaque psoriasis. Idera’s IMO-8400 met both the primary objective of evaluating safety and tolerability for the drug, with no treatment related discontinuation and all patients being well tolerated, and its secondary objective of demonstrating clinical activity in patients with psoriasis.

“Successful completion of this trial is an important additional milestone in our TLR antagonist program. We have studied psoriasis as the initial disease indication to demonstrate clinical proof of concept for our TLR antagonists in autoimmune diseases,” said CEO Sudhir Agrawal, D. Phil. “With these data, we can now pursue our announced business strategy and advance our TLR antagonist drug candidates for the treatment of orphan diseases with high unmet medical need. Towards this goal, our clinical development strategy for IMO-8400 is focused on B-cell lymphomas harboring the MYD88 L265P mutation, and on orphan autoimmune disease indications. Over the remainder of 2014, we anticipate enrolling patients in IMO-8400 trials for Waldenström’s macroglobulinemia, diffuse large B-cell lymphoma and polymyositis and dermatomyositis.”

The treatment showed effectiveness and tolerability at three different dosing levels, giving Idera executives reason for optimism.

“We are very pleased to have met the goals of this trial related to safety and tolerability over three months of dosing, and to have obtained evidence of clinical activity with IMO-8400 in psoriasis patients. This provides further validation of the scientific rationale of blocking over-activation of specific TLRs,” said Senior VP and CMO Lou Brenner, 41M.D. “These data also support our clinical development plans for IMO-8400 in genetically defined forms of B-cell lymphoma and orphan autoimmune diseases.”

However, Summer Street analysts appeared to double down on their initial claims about IMO-8400. Analyst Bart Classen observed that did not mention a dosing effect in the recently-released data, something he considered surprising given it was a dosing study and some patients had very low doses.

The day’s gains may also have generated some interesting technical factors for Idera’s stock. While the release of clinical data is clearly what’s fueling the day’s movement, these other factors could be contributing to the strength of the rebound.

The stock has shown a 14-day stochastic RSI below 0.20 since plunging on Monday, a sign that it’s oversold. And as of yesterday’s losses, the 14-day RSI had also dropped below 30, another sign recognized by traders that the stock is oversold. What’s more, Friday’s gains resulted in the signal line crossing the MACD, which is considered a buy sign.

Finally, the fact that the stock bottomed out at just under $3.70 could show the formation of a rising support line at just under $4 a share based on a hard bounce there in late January. This would play against a clearly defined rising resistance line that’s appeared to cap gains since early September of last year. However, given that this supposed support line would be based on only two bounces, one of which corresponds with the release of positive clinical data, it’s hard to place all that much reliance in it.



Editor's note: this article had previously referred to Summer Street Research Partners as Summer Street Capital Partners, a separate and unafilliated company. It has been edited to correct this mistake.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for IDRA
1 Dec 15 12:45:28
Get the latest ratings for $ERJ $IDRA $TTHI $EFOI $MDAS in your inbox with MarketBeat Daily https://t.co/nSJuDsYidj
Olaf Ray Benson
1 Dec 15 12:30:59
@actaestfabulaXX I had very high hopes for $idra....they keep changing their mind on what kind of company they want to be.
1 Dec 15 12:20:26
$idra $arwr let's get some power hour love com on #bigthangspoppin
1 Dec 15 11:28:08
@108dragonsx @adamfeuerstein What? Ray, my LT position $IDRA shows +40% up, nice stock so far for me ;)
Nathan Michaud
1 Dec 15 10:58:21
$IDRA near red/green
1 Dec 15 10:41:46
Looks like we could get a pop later today $idra it'd make up for weak $arwr
1 Dec 15 10:41:04
IDRA Idera Pharmaceuticals, Inc. Exchange https://t.co/MU4vEQWdnF $IDRA $TERP $VXX $TC #IDRA #stock #investing
1 Dec 15 10:33:35
AGN Allergan plc Day Low https://t.co/otfHWVb2q3 $AGN $GS $SCLN $IDRA #AGN #pennystocks #pennystocks
Britney Salvato
1 Dec 15 10:16:42
RT @thelegacynewswi: Idera Pharmaceuticals Shares Up 5.7% $IDRA https://t.co/PDypl3Y6aD
Options Answers
1 Dec 15 08:52:18
RT @DennyT14: LGIH LGI Homes, Inc. Shares https://t.co/7wHNsLp039 $LGIH $FB $XRT $IDRA #LGIH #stocks #share
1 Dec 15 08:51:33
WMT WPCS Intl Inc. 52Wk Low https://t.co/i81sBBxD7u $WMT $TSLA $ABX $IDRA #WMT #tradeideas #invest
1 Dec 15 08:42:32
LGIH LGI Homes, Inc. Shares https://t.co/7wHNsLp039 $LGIH $FB $XRT $IDRA #LGIH #stocks #share
1 Dec 15 08:42:25
KBIO KaloBios Pharmaceuticals, Inc. Ideas https://t.co/H60RAqd3g0 $KBIO $WMT $IDRA $SLV #KBIO #finance #nasdaq
Honey Adrian
1 Dec 15 08:41:49
RT @InvestorsLive: $IDRA awesome so far!
1 Dec 15 07:59:10
Right now IDRA is number 51 for the largest percentage gain out of 250 stocks. $IDRA IDRA is up +21.63% in the https://t.co/ElfIazHeJk
1 Dec 15 07:50:04
UNG United States Natural Gas Fund Market Cap https://t.co/29psGcaHdT $UNG $GOOG $IDRA $NKE #UNG #share #tradeideas
1 Dec 15 07:48:40
SVXY ProShares Short VIX Short-Term Futures ETF Summary https://t.co/wMp8JlhyJ3 $SVXY $DSLV $GDX $IDRA #SVXY #invest #finance
Greg David
1 Dec 15 07:48:02
IH News Desk
1 Dec 15 07:45:04
PCLN https://t.co/N6PflgnJDn Inc. News https://t.co/e8134Za50Z $PCLN $TRV $NKE $IDRA #PCLN #stocks #stock
Extreme Stocks
1 Dec 15 07:41:19
jim50: IDRA Gapped up +0.03 $IDRA Last Price 3.93 Day https://t.co/FyjesjQsXY
Investors Hangout
1 Dec 15 07:41:11
IDRA Idera Pharmaceuticals, Inc. Filings https://t.co/THzkq3SuDR $IDRA $SVXY $XBI $IBB #IDRA #investing #share
1 Dec 15 07:39:03
GBSN Great Basin Scientific, Inc. Last Price https://t.co/x1WSXJVZnU $GBSN $IDRA $NVDA $AAPL #GBSN #nasdaq #tradeideas
1 Dec 15 07:38:33
IDRA Gapped up +0.03 $IDRA Last Price 3.93 Day High 3.90 Day Low 3.90 Change +0.05 Volume 29,392 Today 62 stoc https://t.co/JsIndH7VG3
1 Dec 15 07:37:33
EXPE Expedia, Inc Prev Close https://t.co/VNzqK44eob $EXPE $IDRA $AKS $ASTI #EXPE #finance #pennystocks
Trader Daily
1 Dec 15 07:15:16
Today's Weak On High Volume Stock: Idera Pharmaceuticals $IDRA $IDRA https://t.co/Q2nZQRvVd6
1 Dec 15 06:49:56
https://t.co/kltyKJ2RKb Stocks in Play: $TWO $AMCC $IDRA $GFA $GTI $TXMD $PSUN $DSUS $BDSI $ASX $ENZN $EGFEY $TRQ
Mark Trader
1 Dec 15 06:43:18
Highly consistent and profitable stock picks at https://t.co/fwYHfOWcRy. Free!! Related: $IDRA $BTU $VOIS $ZNGA $MNKD $NTEK $ISBG
1 Dec 15 06:30:23
$IDRA Max Pain = 3.00. Maturity = 12/18/2015. Previous close = 3.90. https://t.co/fK1JnM2Nmu
Janie Tracey
1 Dec 15 06:24:44
RT @newswithvalue: $IDRA: Zacks: Idera Pharmaceuticals Inc (NASDAQ:IDRA) Receives …: https://t.co/q2gBVoWYWw
RB Trader
1 Dec 15 06:22:22
$IDRA pushing higher after big call volume past two days
1 Dec 15 06:14:45
Small Biotechs moving pre-market $BLRX $IDRA and big move coming in $XOMA
1 Dec 15 04:58:02
$IDRA $FOLD $BMY: Healthcare Stocks in Action: Idera Pharmaceuticals, Inc. (NASDAQ …: https://t.co/dLwhyOwq5M
Breaking News
1 Dec 15 04:46:09
$IDRA $LUV $DHR: Active Stocks to Watch For: Idera Pharmaceuticals Inc (NASDAQ …: https://t.co/zE9dNVlbDm
Michael Cook
1 Dec 15 04:21:16
3,500% Gains On Stock Picks In 5 Months And An Amazing New Pick Is On The Way! Get It Early: https://t.co/GCmBVIIC8f $QCOR $FCEL $IDRA
Michael James
1 Dec 15 04:20:08
3,500% Gains In 5 Months & A MASSIVE New Pick Is Ready! Check It Out: https://t.co/JL7Dn65Ar0 $QCOR $FCEL $IDRA
Paul Henry
1 Dec 15 04:19:32
Our Subscribers Have Seen Incredible Gains On Our Stock Alerts! Subscribe For Our Future Picks: https://t.co/D3sJ9EuA84 $QCOR $FCEL $IDRA
1 Dec 15 04:19:23
RT @wookie4life: $idra $4.5 - $5.0 possible ahead of $ASH_hematology conf. Should test $4.15 - $4.25 tomorrow. Ride the upper Bol channel…
1 Dec 15 04:18:45
RT @SolarMelt: $IDRA The run is on with P2 results pending for two trials: DLBCL (Q1 2016) and Waldenstrom's Macrogloulinemia (DEC 9th at A…
Daniel Wilkinson
1 Dec 15 04:07:52
Rebecca Bootman
1 Dec 15 04:01:53
$IDRA game on.. break hod.. GERN slowing for now. on watch.
1 Dec 15 03:30:10
RT @BosBizDon: Idera Pharma shares now up in past week on new hires, new website & new key trial data coming Saturday $IDRA https://t.co/r6…
1 Dec 15 03:29:51
RT @RatingsNetwork: Idera Pharmaceuticals's overweight rating reiterated at Piper Jaffray. $7.00 PT. https://t.co/qrIe7rSaYc $IDRA #IDRA
1 Dec 15 03:29:49
RT @SleekMoneycom: Idera Pharmaceuticals Inc $IDRA Given Overweight Rating at Piper Jaffray https://t.co/I9CEy8cy6p
Janie Tracey
1 Dec 15 02:48:48
RT @firsttomarkets: Idera Pharmaceuticals, Inc. Reiterated Rating by Piper Jaffray (Ranked 54th) to Overweight with 7 PT $IDRA #IDRA https…
odette schaad
1 Dec 15 02:48:42
RT @DozenStocks: SmallCap #Stocks Trend $GERN $FIZZ $SGY $CJES $WRLD $CECO $MGPI $WTI $REGI $SEAC $IDRA $BREW $LSCC more@ https://t.co/Gir…
Sleek Money
1 Dec 15 02:41:44
Idera Pharmaceuticals Inc $IDRA Given Overweight Rating at Piper Jaffray https://t.co/I9CEy8cy6p
1 Dec 15 02:40:32
Idera Pharmaceuticals Inc $IDRA Given Overweight Rating at Piper Jaffray https://t.co/fnibpXjCUn
1 Dec 15 02:37:11
$IDRA: Idera Pharmaceuticals Inc (IDRA) Given Overweight Rating at Piper …: https://t.co/9b761ElUI6
delila jemenez
1 Dec 15 02:26:55
RT @nasdaqfan: XBI SPDR S&P Biotech Index ETF E.P.S. https://t.co/boluwfK0mS $XBI $SLW $IDRA $BTU #XBI #pennystocks #stockmarket
tory koehly
1 Dec 15 02:16:43
RT @wookie4life: $idra GSK news and upcoming conf will maintain upward momentum. Would not surprise me if Baker Bros added to their holdin…
By  +Follow March 27, 2014 11:11AM



blog comments powered by Disqus

 Today's Must Reads

What Crowdfunding Leaders Are Saying About the SEC’s Approval of Title III

How the Drug Price Scrutiny is Affecting Pharma Stocks

8 More Tips for Choosing the Right Crowdfunding Platform

Will the Post-Smartphone Era Bring Wearable Drones?

3 Cloud Stocks That Pay Dividends


Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register